Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Changhua site meets international regulatory standards for global medical applications
The MDR certification reafirms that these products meet the highest safety, quality, and regulatory standards
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Rad-Sure blood irradiation indicators are FDA 510 (k) cleared medical devices that offer positive visual verification of irradiation at the minimum specified dose
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Decision on EU marketing authorisation expected for momelotinib by early 2024
Subscribe To Our Newsletter & Stay Updated
